Meyka Pro banner
Hangzhou Tigermed Consulting Co., Ltd

Hangzhou Tigermed Consulting Co., Ltd (3347.HK) Stock Competitors & Peer Comparison

See (3347.HK) competitors and their performances in Stock Market.

3347.HKHKSE
HealthcareBiotechnology
HK$37.84
HK$0.30(0.80%)
Hong Kong Market is Open · 15:51

Peer Comparison Table: Biotechnology Industry

Detailed financial metrics including price, market cap, P/E ratio, and more.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
3347.HKHK$37.76+0.59%46.3B39.06HK$0.98+0.38%
4332.HKHK$1,850.00+0.00%998.5B45.81HK$40.38N/A
6160.HKHK$191.10-0.98%265B88.84HK$2.21N/A
2269.HKHK$39.14+0.82%160.9B30.39HK$1.28N/A
1801.HKHK$92.05-0.11%160.6B169.64HK$0.54N/A
6990.HKHK$517.50+1.17%120.6B-256.32-HK$2.02N/A
9926.HKHK$100.40+6.13%91B-73.72-HK$1.34N/A
1530.HKHK$17.62+4.14%43.2B4.50HK$3.84+1.45%
6821.HKHK$118.40-3.27%42.9B38.98HK$3.05+1.26%
2096.HKHK$13.10-0.53%34.2B22.48HK$0.59+1.55%
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

3347.HK vs 4332.HK Comparison July 2026

3347.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 3347.HK stands at 46.3B. In comparison, 4332.HK has a market cap of 998.5B. Regarding current trading prices, 3347.HK is priced at HK$37.76, while 4332.HK trades at HK$1,850.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

3347.HK currently has a P/E ratio of 39.06, whereas 4332.HK's P/E ratio is 45.81. In terms of profitability, 3347.HK's ROE is +0.04%, compared to 4332.HK's ROE of N/A. Regarding short-term risk, 3347.HK is more volatile compared to 4332.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 3347.HK.Check 4332.HK's competition here

Stock price comparison of stocks in the Healthcare Sector

Loading...

Frequently Asked Questions